Search





Search





Markets
/
Stocks
/
eprx
/

Eupraxia Pharmaceuticals Inc

EPRX

Add to Watchlist

6.400USD

-0.150-2.29%

Close 07-31 16:00（ET）Quotes delayed by 15 min

416.54MMarket Cap

LossP/E TTM

Eupraxia Pharmaceuticals Inc

6.400

-0.150-2.29%

Financial Summary Income Statement Balance Sheet Cash Flow Statement

Overview

Financials

Discussions

Analysis

Company

Financial Summary Income Statement Balance Sheet Cash Flow Statement

EPRX Cash Flow Statement

You can access the annual and quarterly cash flow statements of Eupraxia Pharmaceuticals Inc to evaluate its financial soundness and stability.

Quarterly

Quarterly+Annual

Quarterly

Annual

YOY

Hide blank rows

FY2026Q1

FY2025Q4

FY2025Q3

FY2025Q2

FY2025Q1

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022Q3

FY2022Q2

FY2022Q1

FY2021Q4

FY2021Q3

FY2021Q2

FY2021Q1

FY2020Q4

FY2020Q1

FY2019Q4

Operating cash flows (indirect method)

Cash flow from continuing operating activities

-69.03%-10.15M

-62.87%-9.73M

55.77%-4.51M

-7.82%-8.32M

1.92%-6.00M

-0.13%-5.97M

-71.41%-10.19M

-80.53%-7.71M

-34.01%-6.12M

---5.96M

-31.92%-5.94M

-46.33%-4.27M

-48.93%-4.57M

-128.69%-4.51M

15.26%-2.92M

11.22%-3.07M

-3236.77%-2.82M

---1.97M

---3.45M

-1019.75%-3.45M

89.39%-84.47K

--375.57K

---796.25K

Net income from continuing operations

-87.00%-12.65M

-121.99%-16.72M

-6.31%-6.37M

-44.26%-8.75M

-9.91%-6.77M

28.99%-7.53M

-22.37%-5.99M

36.21%-6.06M

-55.63%-6.16M

---10.61M

-33.24%-4.90M

-93.15%-9.51M

-33.29%-3.96M

9.92%-3.67M

-8.11%-4.92M

57.59%-2.97M

-2692.83%-3.00M

---4.08M

---4.55M

-336.16%-7.00M

80.13%-107.30K

---1.60M

---540.09K

Operating gains losses

93.92%90.15K

81.91%72.81K

152.90%62.99K

129.41%55.43K

86.40%46.49K

30.50%40.02K

-11.01%24.91K

-11.89%24.16K

-6.95%24.94K

--30.67K

-26.79%27.99K

-28.45%27.42K

-13.75%26.80K

62.80%38.23K

131.87%38.32K

94.45%31.08K

92.97%32.85K

--23.48K

--16.53K

-58.72%15.98K

-57.93%17.02K

--38.72K

--40.46K

Other non-cash items

-3118.97%-2.27M

2136.25%1.45M

-5289.45%-349.72K

1233.55%734.71K

-144.83%-70.55K

-9.75%-71.19K

199.38%6.74K

965.31%55.09K

1858.76%157.39K

---64.86K

97.02%-6.78K

93.32%-6.37K

-116.91%-8.95K

-102.45%-227.37K

-130.36%-95.37K

-96.54%52.92K

4089092.59%31.38K

---112.31K

--314.13K

--1.53M

100.06%0.77

--0.00

---1.32K

Change in working capital

496.26%2.80M

-140.72%-231.59K

135.90%1.70M

48.12%-1.48M

-382.83%-707.40K

-89.69%568.72K

-1769.99%-4.74M

-392.93%-2.84M

117.63%250.11K

--5.52M

128.61%283.77K

-41.27%971.06K

-77.86%-1.42M

-160.18%-991.85K

720.55%1.65M

46.03%-797.79K

-30.92%-525.31K

--1.65M

--201.50K

-228.46%-1.48M

33.16%-401.25K

--1.15M

---600.28K

-Change in receivables

376.24%23.96K

-189.16%-528.27K

-114.43%-7.28K

724.89%112.77K

-150.43%-8.68K

-47.09%-182.69K

382.61%50.43K

-62.70%13.67K

919.02%17.20K

---124.21K

-66.49%-17.84K

-22.75%36.65K

128.76%1.69K

78.20%-10.72K

-86.71%47.45K

-105.25%-5.87K

43.63%-259.69K

---49.17K

--356.89K

-88.73%111.76K

51.21%-460.70K

--991.48K

---944.16K

-Change in prepaid expenses

533.66%1.24M

-1127.81%-1.47M

900.99%556.37K

-118.00%-1.93M

56.26%195.64K

-1907.53%-119.41K

-198.29%-69.46K

-270.84%-884.75K

143.49%125.20K

---5.95K

-37.00%70.67K

-16.13%-238.58K

32303.54%51.42K

-35.10%112.17K

-218.07%-205.45K

100.07%158.69

10105.65%179.17K

--172.84K

---64.59K

-4902.91%-236.04K

-97.15%1.76K

--4.91K

--61.52K

-Change in payables and accrued expense

272.13%1.54M

102.43%1.76M

124.41%1.15M

117.24%340.20K

-930.33%-894.36K

-84.58%870.82K

-2143.74%-4.72M

-268.24%-1.97M

107.32%107.71K

--5.65M

121.12%230.95K

-35.24%1.17M

-85.85%-1.47M

-171.71%-1.09M

2094.85%1.81M

41.50%-792.08K

-236.08%-444.80K

--1.52M

---90.80K

-977.19%-1.35M

15.76%326.86K

--154.35K

--282.37K

Cash from non-recurring investing activities

Cash from operating activities

-69.03%-10.15M

-62.87%-9.73M

55.77%-4.51M

-7.82%-8.32M

1.92%-6.00M

-0.13%-5.97M

-71.41%-10.19M

-80.53%-7.71M

-34.01%-6.12M

---5.96M

-31.92%-5.94M

-46.33%-4.27M

-48.93%-4.57M

-128.69%-4.51M

15.26%-2.92M

11.22%-3.07M

-3236.77%-2.82M

---1.97M

---3.45M

-1019.75%-3.45M

89.39%-84.47K

--375.57K

---796.25K

Investing cash flow

Net cash from continuing investing activities

93.41%326.95K

341.76%193.30K

42.82%60.38K

1041.14%166.22K

2389.97%169.04K

-11.40%43.76K

340.27%42.27K

-379.37%-17.66K

-15.85%6.79K

--49.38K

-75.32%9.60K

-95.12%6.32K

50.79%8.07K

-88.01%38.91K

11844.70%129.56K

78.29%5.35K

--14.34K

--324.46K

--1.08K

111.45%3.00K

--0.00

---26.22K

--0.00

Capital expenditures

93.41%326.95K

336.20%193.30K

42.82%60.38K

1432.31%166.22K

2389.97%169.04K

-10.27%44.31K

340.27%42.27K

71.59%10.85K

-15.85%6.79K

--49.38K

-75.32%9.60K

-95.13%6.32K

50.79%8.07K

-88.01%38.91K

11867.10%129.80K

78.29%5.35K

--14.34K

--324.46K

--1.08K

--3.00K

--0.00

Net cash flow from disposal of fixed assets

93.41%326.95K

341.76%193.30K

42.82%60.38K

1041.14%166.22K

2389.97%169.04K

-11.40%43.76K

340.27%42.27K

-379.37%-17.66K

-15.85%6.79K

--49.38K

-75.32%9.60K

-95.12%6.32K

50.79%8.07K

-88.01%38.91K

11844.70%129.56K

78.29%5.35K

--14.34K

--324.46K

--1.08K

111.45%3.00K

--0.00

---26.22K

--0.00

Net cash flow from investment products

---79.72M

----

--0.00

---7.05M

----

---7.14M

----

Net cash flow from other investing activities

----

--0.00

----

-100.00%0.00

--0.00

100.00%0.00

--3.44K

--32.60K

--0.00

-9364.72%-4.00M

100.00%0.00

---42.25K

---73.44K

Cash from non-current investing activities

Net cash flow from investing activities

-47255.43%-80.05M

-341.76%-193.30K

-42.82%-60.38K

-1041.14%-166.22K

-2389.97%-169.04K

11.40%-43.76K

-340.27%-42.27K

379.37%17.66K

15.85%-6.79K

---49.38K

75.32%-9.60K

99.91%-6.32K

-50.79%-8.07K

86.67%-38.91K

-661543.71%-7.18M

99.87%-5.35K

---7.15M

---291.86K

---1.08K

-24865.32%-4.00M

100.00%0.00

---16.03K

---73.44K

Financing cash flow

Cash flow from continuous financing activities

15852.39%68.58M

-95.30%1.49M

1706.03%73.90M

105.33%239.78K

-98.14%429.92K

532658.26%31.73M

-128.25%-4.60M

-198.01%-4.50M

11797.52%23.15M

--5.96K

45515.00%16.29M

-55.80%4.59M

645.93%194.61K

-111.31%-35.86K

37.90%10.39M

-100.11%-35.65K

9.26%-117.58K

--317.06K

--7.53M

4237.05%31.91M

-115.54%-129.58K

---771.33K

--833.92K

Net cash flow from debt Issuance/repayment

----

--0.00

100.00%0.00

----

100.00%0.00

-22915.61%-4.60M

-127324.75%-4.50M

-3.36%-36.82K

---20.30K

44.26%-19.99K

90.07%-3.53K

0.08%-35.62K

-111.31%-35.86K

-100.47%-35.55K

-101.78%-35.65K

-261.06%-82.89K

--317.06K

--7.53M

359.05%2.00M

-93.83%51.47K

---771.33K

--833.92K

Net cash flow from common stock issuance/repurchase

--58.63M

-100.00%0.00

--73.89M

----

--31.71M

-100.00%0.00

--0.00

--22.85M

--0.00

--15.89M

-100.00%0.00

--0.00

--10.42M

----

--30.01M

----

Proceeds from stock option exercised by employees

742.31%113.86K

2278.07%600.01K

--3.75K

--22.32K

96450.00%13.52K

-3.90%25.23K

100.00%0.00

-100.00%0.00

-97.98%14.00

--26.25K

---1.00

--3.11K

--694.00

----

Proceeds from issuance of warrants

2261.69%9.83M

140870.57%890.93K

--3.04K

--217.46K

23.50%416.41K

63300.00%632.00

-100.00%0.00

46.90%337.18K

---1.00

--421.00K

--4.59M

--229.54K

----

Net cash flow from other financing activities

----

--0.00

----

--0.00

-100.00%0.00

-16497.33%-30.05M

--0.00

--29.91M

---181.04K

--0.00

----

Net cash from non-recurrent financing activities

Net cash from financing activities

15852.39%68.58M

-95.30%1.49M

1706.03%73.90M

105.33%239.78K

-98.14%429.92K

532658.26%31.73M

-128.25%-4.60M

-198.01%-4.50M

11797.52%23.15M

--5.96K

45515.00%16.29M

-55.80%4.59M

645.93%194.61K

-111.31%-35.86K

37.90%10.39M

-100.11%-35.65K

9.26%-117.58K

--317.06K

--7.53M

4237.05%31.91M

-115.54%-129.58K

---771.33K

--833.92K

Net cash flow

Beginning cash balance

143.38%80.56M

927.03%88.96M

-15.23%19.77M

-23.54%27.45M

71.14%33.10M

-64.74%8.66M

61.66%23.32M

157.81%35.91M

5.90%19.34M

--24.56M

14.65%14.42M

6.20%13.93M

9.26%18.26M

-55.79%12.58M

-47.76%13.11M

13882.05%16.71M

7805.82%26.65M

--28.46M

--25.11M

-85.46%119.55K

-63.62%337.06K

--822.31K

--926.59K

Current period cash flow changes

-290.73%-22.06M

-134.35%-8.40M

572.17%69.19M

38.93%-7.69M

-134.09%-5.65M

568.04%24.44M

-244.51%-14.65M

-2643.39%-12.59M

482.08%16.57M

---5.22M

336.76%10.14M

23.45%495.06K

-36.91%-4.34M

-123.81%-4.28M

-90.06%401.04K

-112.95%-3.17M

-4634.67%-10.13M

---1.91M

--4.04M

6038.59%24.45M

-498.43%-214.04K

---411.78K

---35.77K

Effect of exchange rate changes

-569.31%-448.18K

102.66%33.89K

-176.78%-137.32K

239.01%552.75K

120.73%95.50K

-262.18%-1.28M

192.83%178.85K

-317.86%-397.62K

-1122.24%-460.76K

--786.49K

-164.69%-192.68K

65.63%182.51K

176.20%45.07K

844.82%297.84K

320.20%110.19K

---59.15K

---47.45K

--31.52K

---50.04K

----

Ending cash balance

113.08%58.50M

143.38%80.56M

927.03%88.96M

-15.23%19.77M

-23.54%27.45M

71.14%33.10M

-64.74%8.66M

61.66%23.32M

157.81%35.91M

--19.34M

187.72%24.56M

6.74%14.42M

3.12%13.93M

-67.85%8.54M

-53.58%13.51M

-45.49%13.51M

13922.10%16.54M

--26.56M

--29.11M

5671.50%24.78M

-86.75%117.93K

--429.31K

--890.25K

Free cash flow

-69.69%-10.47M

-64.89%-9.92M

55.37%-4.57M

-9.82%-8.48M

-0.73%-6.17M

-0.04%-6.02M

-71.84%-10.23M

-80.51%-7.72M

-33.92%-6.13M

---6.01M

-31.00%-5.95M

-40.31%-4.28M

-48.94%-4.58M

-98.05%-4.55M

11.52%-3.05M

11.14%-3.07M

-3253.75%-2.83M

---2.29M

---3.45M

-1020.55%-3.46M

89.39%-84.47K

--375.57K

---796.25K

Currency unit

--USD

Audit opinions

----

FAQs

What is operating cash flow?



Operating cash flow is the cash generated or used by a company's core business operations. It adjusts net income for non-cash items and working capital changes, such as depreciation, receivables, inventory, and payables. Strong operating cash flow can indicate that the business is converting sales and earnings into real cash.

How Much Operating Cash Flow Did Eupraxia Pharmaceuticals Inc Generate?



Eupraxia Pharmaceuticals Inc generated -28.55M in operating cash flow in fiscal 2025, reflecting cash generated from its core business operations.

How Did Eupraxia Pharmaceuticals Inc's Operating Cash Flow Change Year Over Year?



Eupraxia Pharmaceuticals Inc's operating cash flow increased by 4.81% year over year.

What is investing cash flow?



Investing cash flow shows cash used for or generated from investment-related activities, such as capital expenditures, purchases or sales of investments, acquisitions, and asset disposals. Negative investing cash flow is not always bad, because it can reflect spending on future growth, but investors should check whether those investments support long-term returns.

How Much Does Eupraxia Pharmaceuticals Inc Spend on Capital Expenditures?



Eupraxia Pharmaceuticals Inc spent 588.95K on capital expenditures in the most recent quarter。

What is financing cash flow?



Financing cash flow shows how a company raises capital or returns capital to investors and creditors. It can include debt issuance, debt repayment, share issuance, share repurchases, dividend payments, and lease financing. Positive financing cash flow may show new capital raised, while negative financing cash flow may reflect debt repayment, dividends, or buybacks.

How Has Eupraxia Pharmaceuticals Inc's Financing Cash Flow Changed?



Eupraxia Pharmaceuticals Inc used 76.06M in financing activities in the latest quarter.

What is free cash flow and why does it matter for EPRX?



Free cash flow is the cash a company has left after funding the capital spending needed to maintain or grow the business. It is often used to assess financial flexibility, debt repayment capacity, dividend sustainability, buyback potential, and valuation quality. Investors should compare free cash flow with net income, revenue growth, and capital expenditures.

What was Eupraxia Pharmaceuticals Inc’s free cash flow in the latest quarter?



Free cash flow was -29.14M reflecting a 3.18% change from the previous year.